November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
VEXAS Anemia is a Mosaic Erythroblastopenia: A New Publication from Hermine Laboratory
Nov 13, 2025, 23:15

VEXAS Anemia is a Mosaic Erythroblastopenia: A New Publication from Hermine Laboratory

Hermine Laboratory shared on LinkedIn:

”New Publication Alert

We’re excited to share our latest study: “VEXAS syndrome Anemia Is a Mosaic Erythroblastopenia” published in Blood Journal (Rodrigues F. et al., Blood, 2025)

In this work, we reveal that VEXAS-associated anemia is driven by a selective failure of erythroid precursor maturation — the first clear evidence that the condition represents a mosaic erythroblastopenia rather than a uniform red-cell defect.

Key findings include:
• Patient bone-marrow erythroblasts with UBA1 mutations showed lethal early differentiation arrest in edited CD34⁺ cells, mirroring features of other ribosomopathies.

Why it matters
This study advances our mechanistic understanding of VEXAS anemia and offers clues toward potential treatment strategies that focus on restoring healthy erythropoiesis.

We hope this will spark new translational opportunities in the field of hematologic disorders.

Thank you to all our collaborators, patients, and funders who made this work possible.”

Read the full article in Blood.

Article: VEXAS anemia is a mosaic erythroblastopenia

Authors: Francois Rodrigues Corresponding Author , Giulia Hardouin, Sara El Hoss, Aya Ghoul, Emilie-Fleur Gautier, Michaël Dussiot, Maria A. Lizarralde-Iragorri, Annalisa Santini, Sandy Peltier, Pascal Amireault, Vanessa Soldan, Annarita Miccio, Mounia Debili, Vincent Jachiet, Thiago Trovati Maciel, Julien Rossignol, Eric Allemand, Arsène M Mékinian, Sophie Anne Georgin-Lavialle, Pr, Mohammad Salma, Eric Soler, Pierre-Emmanuel Gleizes, Marie-Francoise O’Donohue, Olivier Kosmider, Manuel S. Rodriguez, Olivier Hermine

VEXAS Anemia is a Mosaic Erythroblastopenia: A New Publication from Hermine Laboratory

Stay updated on all scientific advances with Hemostasis Today.